Evolent Health (EVH)
(Delayed Data from NYSE)
$32.73 USD
+0.60 (1.87%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $32.75 +0.02 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.73 USD
+0.60 (1.87%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $32.75 +0.02 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Strong Buy Stocks for January 5th
by Zacks Equity Research
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
How Much Upside is Left in Evolent Health (EVH)? Wall Street Analysts Think 59.66%
by Zacks Equity Research
The consensus price target hints at a 59.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Best Momentum Stocks to Buy for November 20th
by Zacks Equity Research
EVH, ACGL and AREC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 20, 2023.
Wall Street Analysts See a 56.84% Upside in Evolent Health (EVH): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 56.8% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Evolent Health (EVH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 233.33% and 0.55%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Celestica (CLS) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Celestica (CLS) delivered earnings and revenue surprises of 6.56% and 2.42%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Evolent Health (EVH) Could Surge 76.14%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Evolent Health (EVH) points to a 76.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CrowdStrike (CRWD) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
CrowdStrike (CRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Believe Evolent Health (EVH) Could Rally 77.45%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 77.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Evolent Health (EVH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Evolent Health (EVH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 55.56% and 1.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Evolent Health (EVH) Beats Q1 Earnings Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 40% and 1.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Expands Evolent Partnership to Boost Quality
by Zacks Equity Research
Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.
Evolent Health (EVH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 66.67% and 2.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
EngageSmart (ESMT) Matches Q4 Earnings Estimates
by Zacks Equity Research
EngageSmart (ESMT) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Down 29.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolent Health (EVH)
by Zacks Equity Research
Evolent Health (EVH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Evolent Health (EVH) Q3 Earnings Top Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 637.50% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Evolent Health (EVH) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Here is how Evolent Health (EVH) and KVH Industries (KVHI) have performed compared to their sector so far this year.
Is Absolute Software (ABST) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Here is how Absolute Software Corporation (ABST) and Evolent Health (EVH) have performed compared to their sector so far this year.
What Makes Evolent Health (EVH) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Evolent Health (EVH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 28% Upside in Evolent Health (EVH): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 28.3% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Evolent Health (EVH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 233.33% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: New Relic (NEWR) Q1 Earnings Expected to Decline
by Zacks Equity Research
New Relic (NEWR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.